Want to see IN:NATHBIOGEN full AI Analyst Report?
Nath Bio-Genes (India) Ltd. (NATHBIOGEN) Stock Statistics & Valuation Metrics
Total Valuation
Nath Bio-Genes (India) Ltd. has a market cap or net worth of INR 2.50B. The enterprise value is INR 3.05B.
- Market Cap
- INR 2.50B
- Enterprise Value
- INR 3.05B
Share Statistics
Nath Bio-Genes (India) Ltd. has 19,004,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 19,004,000
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Nath Bio-Genes (India) Ltd.’s return on equity (ROE) is 0.06 and return on invested capital (ROIC) is 5.29%.
- Return on Equity (ROE)
- 0.06
- Return on Assets (ROA)
- 0.04
- Return on Invested Capital (ROIC)
- 5.29%
- Return on Capital Employed (ROCE)
- 0.07
- Revenue Per Employee
- 9.85M
- Profits Per Employee
- 921.02K
- Employee Count
- 452
- Asset Turnover
- 0.41
- Inventory Turnover
- 0.54
Valuation Ratios
The current PE Ratio of Nath Bio-Genes (India) Ltd. is 7.11. Nath Bio-Genes (India) Ltd.’s PEG ratio is -0.61.
- PE Ratio
- 7.11
- PS Ratio
- 0.51
- PB Ratio
- 0.37
- Price to FCF
- -2.27
- Price to Operating Cash Flow
- -2.29
- PEG Ratio
- -0.61
Income Statement
In the last 12 months, Nath Bio-Genes (India) Ltd. had revenue of 4.45B and earned 416.30M in profits. Earnings per share was 20.98.
- Revenue
- 4.45B
- Gross Profit
- 2.04B
- Operating Income
- 484.75M
- Pretax Income
- 463.04M
- Net Income
- 416.30M
- EBITDA
- 662.56M
- Earnings Per Share (EPS)
- 20.98
Cash Flow
In the last 12 months, operating cash flow was -1.09B and capital expenditures -11.04M, giving a free cash flow of -1.10B billion.
- Operating Cash Flow
- -1.09B
- Free Cash Flow
- -1.10B
- Free Cash Flow per Share
- -57.77
Dividends & Yields
Nath Bio-Genes (India) Ltd. pays an annual dividend of INR 2.00, resulting in a dividend yield of 1.52%
- Dividend Per Share
- INR 2.00
- Dividend Yield
- 1.52%
- Payout Ratio
- 77.25%
- Free Cash Flow Yield
- -44.10%
- Earnings Yield
- 15.53%
Stock Price Statistics
- Beta
- 1.12
- 52-Week Price Change
- -22.10%
- 50-Day Moving Average
- 143.41
- 200-Day Moving Average
- 153.06
- Relative Strength Index (RSI)
- 38.92
- Average Volume (3m)
- 1,084
Important Dates
Nath Bio-Genes (India) Ltd. upcoming earnings date is Feb 11, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 21, 2026
- Next Earnings Date
- Feb 11, 2027
- Ex-Dividend Date
- Aug 14, 2025
Financial Position
Nath Bio-Genes (India) Ltd. as a current ratio of 1.97, with Debt / Equity ratio of 20.35%
- Current Ratio
- 1.97
- Quick Ratio
- 0.83
- Debt to Market Cap
- 0.54
- Net Debt to EBITDA
- 0.94
- Interest Coverage Ratio
- 3.03
Taxes
In the past 12 months, Nath Bio-Genes (India) Ltd. has paid 46.73M in taxes.
- Income Tax
- 46.73M
- Effective Tax Rate
- 0.10
Enterprise Valuation
Nath Bio-Genes (India) Ltd. EV to EBITDA ratio is 4.06, with an EV/FCF ratio of -2.27.
- EV to Sales
- 0.51
- EV to EBITDA
- 4.06
- EV to Free Cash Flow
- -2.27
- EV to Operating Cash Flow
- -2.29
Balance Sheet
Nath Bio-Genes (India) Ltd. has INR 759.95M in cash and marketable securities with INR 0.00 in debt, giving a net cash position of INR 759.95M billion.
- Cash & Marketable Securities
- INR 759.95M
- Total Debt
- INR 0.00
- Net Cash
- INR 759.95M
- Net Cash Per Share
- INR 39.99
- Tangible Book Value Per Share
- INR 358.06
Margins
Gross margin is 43.23%, with operating margin of 9.25%, and net profit margin of 7.90%.
- Gross Margin
- 43.23%
- Operating Margin
- 9.25%
- Pretax Margin
- 8.86%
- Net Profit Margin
- 7.90%
- EBITDA Margin
- 12.53%
- EBIT Margin
- 11.71%
Analyst Forecast
The average price target for Nath Bio-Genes (India) Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 21.02%
- EPS Growth Forecast
- -3.13%
Scores
- Smart Score
- ―
- AI Score
- 62